Literature DB >> 16581653

The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor.

Cuyan Demirkesen1, Nur Büyükpinarbaşili, Rana Ramazanoğlu, Oya Oğuz, Nil Molinas Mandel, Gültekin Kaner.   

Abstract

AIM: To establish whether there is a correlation between angiogenesis and metastasis in primary cutaneous melanoma (PCMM).
METHODS: We studied the microvessel density and the expression of vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor (bFGF) in 22 cases of PCMM with metastasis at presentation (metastatic group) and 28 cases of PCMM without metastasis for 24 months or more (non-metastatic group). Microvessels were stained with CD31/PECAM-1 antibody and counted. We assessed the proportion of VEGF expression in tumour cells, lymphocytes infiltrating the tumour (TIL) and lymphocytes at the periphery of the tumour, as well as the proportion of bFGF expression in tumour cell cytoplasms, nuclei and intra- and peritumoral vessels.
RESULTS: An increased microvessel density was detected in the metastatic group (15-33 [24.09 +/- 5.55] versus 2-24 [12.96 +/- 6.02]). Moreover, enhanced expression of VEGF in tumour cells and peritumoral lymphocytes (Chi-square p = 0.038 and p = 0.018) and bFGF in peritumoral vessels (chi(2) p = 0.013) correlated with the simultaneous presence of melanoma metastasis in PCMM. Furthermore, microvessel density was correlated with the expression of bFGF in peritumoral vessels (rs = 0.53, p = 0.049) and VEGF in tumour cells (rs = 0.37, p = 0.019).
CONCLUSION: Microvessel density as well as the expression of both VEGF and bFGF might be informative concerning the progression of melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581653     DOI: 10.1080/00313020600557565

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  13 in total

1.  Lack of correlation between microvascular density and pathological features and outcomes in sinonasal and oral mucosal melanomas.

Authors:  Elizabeth H Kerr; Dezhi Wang; James S Lewis; Nasser Said-Al-Naief; Omar Hameed
Journal:  Head Neck Pathol       Date:  2011-03-19

2.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

3.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

4.  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Authors:  Richard D Carvajal; Michael K Wong; John A Thompson; Michael S Gordon; Karl D Lewis; Anna C Pavlick; Jedd D Wolchok; Patrick B Rojas; Jonathan D Schwartz; Agop Y Bedikian
Journal:  Eur J Cancer       Date:  2014-06-12       Impact factor: 9.162

5.  Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Authors:  Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

6.  Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.

Authors:  Tim D Eubank; Ryan D Roberts; Mahmood Khan; Jennifer M Curry; Gerard J Nuovo; Periannan Kuppusamy; Clay B Marsh
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

Review 7.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

8.  Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo.

Authors:  Liangru W Contois; Abebe Akalu; Jennifer M Caron; Eric Tweedie; Alexandra Cretu; Terry Henderson; Lucy Liaw; Robert Friesel; Calvin Vary; Peter C Brooks
Journal:  Angiogenesis       Date:  2014-09-24       Impact factor: 9.596

9.  Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.

Authors:  Patrick Terheyden; Maja Ann Hofmann; M Weininger; Eva-B Bröcker; Jürgen C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-22       Impact factor: 4.553

10.  Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.

Authors:  Ferdinand Toberer; Holger A Haenssle; Martin Laimer; Monika Heinzel-Gutenbrunner; Alexander Enk; Wolfgang Hartschuh; Peter Helmbold; Heinz Kutzner
Journal:  Acta Derm Venereol       Date:  2020-08-18       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.